10-K: Galectin Therapeutics 2025 10-K: NAVIGATE Trial Results & Funding

Galectin Therapeutics reports 2025 annual results, highlighting mixed NAVIGATE trial outcomes for belapectin in MASH cirrhosis and ongoing financing needs.

Summary

• Galectin Therapeutics is a clinical-stage biopharmaceutical company focused on developing new therapies for fibrotic disease and cancer by targeting galectin proteins.
• The lead drug candidate, belapectin (GR-MD-02), is a galectin-3 inhibitor being developed for MASH (metabolic dysfunction-associated steatohepatitis) with cirrhosis and certain cancer indications.
• The large, global Phase 2b/3 NAVIGATE clinical trial for the prevention of esophageal varices in MASH cirrhosis patients completed randomization in February 2023, with top-line results presented in December 2024.
• In the intent-to-treat (ITT) population (N=355), the incidence of varices was 43.2% reduced in the belapectin 2 mg/kg dose group versus placebo, but the composite endpoint did not reach statistical significance.
• In the pre-defined per-protocol population (PPP, n=287), the incidence of varices was reduced by 49.3% (p-value < 0.05) in the belapectin 2 mg/kg dose group.
• A further analysis of the US completer patients (n=186) in the NAVIGATE trial showed a significant 68.1% reduction (p=0.02) in the incidence of varices with belapectin 2 mg/kg.
• Belapectin demonstrated consistent, meaningful effects across multiple key biomarkers in MASH cirrhosis, including fewer patients experiencing clinically significant worsening of liver stiffness (LSM) and improvements in ELF (Enhanced Liver Fibrosis) score.
• The safety profile of belapectin remained highly encouraging, with adverse events and serious adverse events comparable across all three cohorts in the NAVIGATE trial, and no drug-related SAEs reported.
• The company incurred a net loss of $30.8 million in 2025, compared to $47.0 million in 2024, and has an accumulated deficit of $431 million as of December 31, 2025.
• Cash and cash equivalents totaled $17.7 million as of December 31, 2025, with an additional $10 million available under a line of credit from the chairman, expected to fund operations through April 2027.
• A follow-up Type C meeting with the FDA is planned to finalize the design for the next clinical trial for belapectin in MASH cirrhosis.
• Development in immuno-oncology for advanced or metastatic head and neck cancer with belapectin in combination with a checkpoint inhibitor is also being pursued, with a proposed Phase 2 trial dependent on financing.
• A material weakness in internal control over financial reporting was identified related to the valuation of derivative liabilities associated with contingent interest on convertible notes payable.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging report due to the primary endpoint miss in the NAVIGATE trial, despite positive subgroup data, coupled with ongoing significant losses and dependence on external financing for future development.

Positives

• Belapectin 2 mg/kg dose showed a 49.3% reduction in varices incidence (p-value < 0.05) in the per-protocol population (n=287) of the NAVIGATE trial, compared to a targeted 52.5% reduction.
• The US subgroup (n=186) of the NAVIGATE trial demonstrated a significant 68.1% reduction (p=0.02) in varices incidence with belapectin 2 mg/kg (4 out of 60 patients) versus placebo (13 out of 62 patients).
• Belapectin demonstrated consistent, meaningful effects across multiple key biomarkers in MASH cirrhosis, including fewer patients experiencing clinically significant worsening of liver stiffness (LSM) and improvements in the ELF (Enhanced Liver Fibrosis) score.
• Treatment with belapectin was associated with a reduced presence of clinically significant portal hypertension (CSPH) and a lower risk of hepatic decompensation at 18 months, based on Baveno VII criteria.
• The safety profile of belapectin remains highly encouraging, with incidence of adverse events and serious adverse events comparable across the three cohorts in the NAVIGATE trial, and no drug-related SAEs reported.
• Favorable results were reported in 2023 from a hepatic impairment study (NCT04332432), indicating that belapectin exposure did not increase with the degree of hepatic insufficiency.
• Promising results were reported in a Phase 1b trial combining belapectin with pembrolizumab (KEYTRUDA) in advanced melanoma (50% objective response rate) and head and neck cancer (33% response rate).
• There was a suggestion that the combination of belapectin with pembrolizumab could decrease the auto-immune side-effects induced by pembrolizumab, which can be severe enough to lead to treatment interruption.
• The company held 20 granted U.S. patents and 97 foreign granted patents as of December 31, 2025, with scheduled expiration dates extending to 2034, providing intellectual property protection.

Negatives

• The composite endpoint of the NAVIGATE clinical trial did not reach statistical significance in the intent-to-treat (ITT) population (N=355), despite a 43.2% reduction in varices incidence in the belapectin 2 mg/kg dose group.
• The company incurred a net loss of $30.8 million in 2025 and $47.0 million in 2024, with an accumulated deficit of $431 million as of December 31, 2025.
• No revenues have been generated from operations since the company's inception in July 2000.
• The company is dependent on additional capital to fund operations beyond April 2027, with no assurance of obtaining such financing on favorable terms or at all.
• The proposed Phase 2 trial for advanced or metastatic head and neck cancer is dependent on securing financing, indicating a potential delay in its commencement.
• A material weakness was identified in internal control over financial reporting related to the valuation of derivative liabilities associated with contingent interest on convertible notes payable.
• Research and development expenses decreased significantly to $14.3 million in 2025 from $36.6 million in 2024, primarily due to winding down NAVIGATE clinical trial activities and a decrease in contract manufacturing costs, suggesting a reduction in active development pace.

Risks

• The company has incurred net losses since inception and must raise additional capital to continue operations, with no assurance of obtaining new financing on favorable terms or at all.
• Significant dependence on Richard E. Uihlein, the chairman of the board, for financing, with no assurance he will continue to provide funding beyond existing commitments.
• The NAVIGATE trial's composite endpoint did not reach statistical significance, which may lead to a decision not to conduct an additional clinical trial or difficulties in securing funding and regulatory alignment for a pivotal Phase 3 trial.
• The company has from time to time faced substantial doubt about its ability to continue as a going concern, with existing cash resources projected to fund operations only through April 2027.
• There is no assurance of obtaining FDA approval for belapectin or other product candidates, or of generating sufficient revenue to achieve profitability.
• Pre-clinical studies and clinical trials are expensive, time-consuming, and may not be successful; previous trials (NASH-CX, NASH-FX) did not meet primary endpoints.
• Dependence on third parties for clinical trial design, execution, and manufacturing, whose failure to perform could adversely affect the business.
• Exposure to pre-clinical and clinical liability risks without sufficient product liability insurance beyond general coverage.
• Intense competition in the biotechnology and pharmaceutical industries from companies with greater financial and other resources.
• The market for proposed products is rapidly changing and competitive, with new drugs and treatments potentially rendering current products noncompetitive or obsolete.
• Potential widespread acceptance of alternative therapies may limit market acceptance of the company's proposed products.
• Lack of operating experience in commercial manufacturing, later-stage regulatory processes, sales, and marketing could harm business growth.
• High dependence on a few key individuals; loss of personnel could prevent product development and collaborative relationships.
• Failure to comply with reporting and other requirements under federal securities laws could lead to penalties and restrict access to financing.
• A material weakness in internal control over financial reporting related to derivative liabilities valuation could result in material misstatements if not remediated.
• Long-term success is dependent on capitalizing on potential positive trial results, which is not assured, and securing sufficient cash and drug dosages for future trials.
• Potential for future shareholder litigation or governmental investigations, which could divert management's attention and incur significant expenses.
• Regulatory approvals are lengthy, expensive, and uncertain, and the FDA may change requirements, leading to delays or non-approvals.
• Even if regulatory approvals are obtained, marketed drugs will be subject to ongoing regulatory review, and failure to comply could lead to loss of approvals.
• Clinical trial data may be negative, inconclusive, or subject to varying interpretations, and product candidates may cause undesirable side effects, delaying or preventing regulatory approval.
• Failure to obtain regulatory approval in international jurisdictions would prevent product candidates from being marketed abroad.
• Inability to adequately protect proprietary intellectual property, including patent challenges, litigation, or competitors practicing technologies.
• Reliance on information technology and third-party systems exposes the company to cybersecurity breaches and data leakage.
• The market price of common stock may be volatile and adversely affected by various factors, potentially leading to securities class action litigation.
• The board of directors has the power to designate additional series of preferred capital that could be senior to common stock.
• Nevada law and charter documents could make it more difficult for a third party to acquire the company, potentially depressing the stock price.
• Issuance of additional common stock, particularly for capital raises, might dilute the net tangible book value per share and percentage ownership.
• Sales of a substantial number of shares by principal stockholders could cause the stock price to decline or result in a change in control.
• A pandemic similar to COVID-19 could adversely impact business, preclinical studies, and clinical trials, including delays in enrollment, disruptions in experiments, and interruptions in regulatory operations.

Future Outlook

The company plans a follow-up Type C meeting with the FDA to finalize the design for the next clinical trial for belapectin in MASH cirrhosis. A proposed Phase 2 trial for advanced or metastatic head and neck cancer is dependent on securing financing. The company anticipates existing cash resources, including a $10 million line of credit, will fund operations through April 2027, but will require more cash thereafter.

Management Comments

• "We are undertaking the focused pursuit of therapies for indications where galectin proteins have a demonstrated role in the pathogenesis of a given disease."
• "Our strategy is to establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when one of our programs becomes advanced and requires significant additional resources."
• "We believe that the prevention of esophageal varices is a clinically relevant endpoint related to patient outcomes."
• "We believe that this goal [stopping progression and/or reversing portal hypertension and thereby preventing the development of varices] is achievable in a significant portion of the MASH cirrhosis patient population."
• "We believe there is potential for galectin inhibition to play a key role in the innovative area of cancer immunotherapy."
• "We believe these data, taken together with the observed favorable safety and tolerability of the combination, provide a rationale to move the belapectin program in oncology forward."
• "The decision [to pursue recurrent or metastatic head and neck cancer] is notably based on the lack of available treatments for these patients, the limited number of therapies in development, and the resulting very high medical need."

Industry Context

StockSavvy.ai notes that Galectin Therapeutics operates in highly competitive biopharmaceutical sectors, particularly MASH and cancer immunotherapy. The MASH landscape is evolving with increasing focus on non-invasive markers and prevention of complications like varices, where belapectin shows promise in specific patient subgroups. In immuno-oncology, the strategy of combining galectin-3 inhibition with checkpoint inhibitors like pembrolizumab aligns with broader industry trends seeking to enhance immune responses and mitigate side effects, potentially offering a differentiated approach in areas of high unmet need like recurrent or metastatic head and neck cancer.

Comparison to Industry Standards

• The NAVIGATE trial enrolled one of the most advanced MASH cirrhosis patient populations among recent trials, as evidenced by the high proportion of subjects meeting clinically significant portal hypertension (CSPH) criteria at baseline.
• The 50% objective response rate observed in advanced melanoma with belapectin in combination with KEYTRUDA (pembrolizumab) compares favorably to historical monotherapy rates for checkpoint inhibitors in this indication, which typically range from 30-40%.
• The 33% response rate documented in head and neck cancer patients with the combination therapy is notable given the limited treatment options and high medical need in recurrent or metastatic settings, where single-agent checkpoint inhibitor response rates can be lower.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material, adverse effect on financial condition or results of operations.
• Previously a defendant in a state court shareholder derivative action that concluded in the company's favor.
• Involved in a dispute with a contract vendor for clinical trial management services provided outside of the United States, for which an estimated amount owed has been accrued.

Related Party Transactions

• Richard E. Uihlein, the chairman of the board, provided multiple convertible lines of credit to the company in 2025, including a March 2025 Supplemental Line of Credit (up to $5.0 million), a July 2025 Supplemental Line of Credit (up to $10.0 million), and a December 2025 Supplemental Line of Credit (up to $10.0 million).
• Advances under these lines of credit are evidenced by unsecured, convertible promissory notes bearing interest at the Applicable Federal Rate plus two percent, and include warrants to purchase common stock.
• Mr. Uihlein irrevocably elected to convert the entire principal and accrued interest of the April 2021 Note into common stock at $5.00 per share, effective as of June 30, 2027 (extended maturity date).
• The maturity dates for the September 2021 Note and December 2021 Note (each $10 million principal from Mr. Uihlein) were extended to June 30, 2027.
• As of February 28, 2026, Mr. Uihlein beneficially owns approximately 49.4% of the company's outstanding common stock (including convertible securities).
• One director elected to receive restricted stock in lieu of cash retainer for their service in 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings and the conversion of existing debt and warrants into common stock. The significant ownership concentration by Mr. Uihlein and 10X Fund, L.P. may limit the influence of other stockholders on corporate actions.
• Employees are subject to a compensation program designed to attract, retain, and reward, including base salary, performance bonuses, and long-term equity awards. The company's dependence on a few key individuals for research and development and clinical studies highlights the importance of retaining this talent.
• Creditors, particularly Richard E. Uihlein, are significant stakeholders due to the substantial convertible notes and lines of credit provided to the company.
• Patients with MASH cirrhosis may see potential benefits from belapectin in specific subgroups (per-protocol population, US subgroup) for preventing esophageal varices and improving biomarkers, but the failure of the overall NAVIGATE trial to meet its primary endpoint creates uncertainty regarding future treatment availability.
• Patients with advanced or metastatic head and neck cancer represent a high medical need, and the proposed Phase 2 trial for belapectin in combination with a checkpoint inhibitor offers a potential new therapeutic option, contingent on securing financing.

Next Steps

• Pursue a follow-up Type C meeting with the FDA to finalize the design for the next clinical trial for belapectin in MASH cirrhosis.
• Review options for financing the proposed Phase 2 trial for advanced or metastatic head and neck cancer.
• Identify and develop small molecule galectin-3 inhibitors through the majority-owned joint venture subsidiary, Galectin Sciences LLC.
• Remediate the identified material weakness in internal control over financial reporting related to derivative liabilities valuation through additional training and third-party consultants.
• Seek additional capital through debt or equity financings, collaborations, partnerships, or other strategic transactions beyond April 2027.

Key Dates

Recommendation

The mixed results from the NAVIGATE trial, particularly the failure to meet the primary composite endpoint in the ITT population, present a significant challenge for immediate regulatory approval and future commercialization of belapectin for MASH cirrhosis. While positive signals in subgroups (PPP, US) and biomarker improvements offer some hope, the path forward is uncertain and requires further FDA alignment and substantial financing. The company's heavy reliance on a single individual for funding and its ongoing net losses add to the financial risk. However, the promising early data in immuno-oncology and the potential for belapectin to address high unmet medical needs in cancer provide a speculative upside. Given the current uncertainties and the need for further clarity on clinical and financial pathways, a 'hold' recommendation is appropriate for investors who are already exposed and willing to monitor developments closely, but new investment carries substantial risk.

Keywords

Galectin Therapeutics, GALT, belapectin, MASH, NASH, cirrhosis, liver fibrosis, esophageal varices, NAVIGATE trial, clinical trial, galectin-3 inhibitor, immuno-oncology, head and neck cancer, biopharmaceutical, drug development, SEC filing, 10-K, financial results, capital raise, corporate governance, risk factors, biomarkers, FDA